How GCS-GCRI Enriched Me
Journal Title: GUJARAT CANCER SOCIETY RESEARCH JOURNAL - Year 2018, Vol 20, Issue 1
Abstract
Prologue: It is my great pleasure to receive Shri Madanmohan Ramanlal GCRI Luminary Oration Award which is envisaged as a Life-Time Award for its recipients. Shri Madanmohan Ramanlal was a karmayogi, a philanthropist and a deeply religious man with highest priority on ethics and business morals. The award is given away to a senior GCRIan for his/her contribution to GCRI, to his/her discipline, science in general, professional organizations and society at large. It is said that it is awarded to a compassionate teacher who is a source of inspiration to generations of students. Seven GCRI Luminaries have adorned and embellished this recognition.
Authors and Affiliations
Dr. Shilin Shukla
Keywords
Related Articles
- EP ID EP474001
- DOI -
- Views 46
- Downloads 0
A Study of Immune Dysfunction in Patients with Breast Carcinoma
Immune system play a major role in malignant transformation and to understand the role of immune cells in breast carcinoma. We have evaluated lymphocytes, monocytes, neutrophils, ALC (absolute lymphocyte count), AMC (abs...
Circulating Tumor Cells (CTCs) or Cancer Stem Cells (CSCs): The Unresolved Paradox as Drivers of Metastasis
Summary Tumor aggressiveness, relapse and metastasis are the primary causes of poor survival rates in patients with advanced stage cancer despite successful resection as well as chemotherapeutic treatment which limits th...
Shri R J Kinarivala Research Oration Award, Year - 2016
From Chromosomes to Therapy: A Passage to Translational Medicine in Non-Hodgkin Lymphoma
Parathyroid Carcinoma- A Case Report
Parathyroid carcinoma is a rare endocrine neoplasm. Although most patients present with hyperparathyroidism, it is difficult to distinguish preoperatively parathyroid carcinoma from its benign counterpart (parathyroid ad...
Progress in the Treatment of Myeloma
Multiple myeloma is a malignancy of plasma cells which affects more than 30,000 sufferers and their families in the UK. Myeloma comprises 15% of all lymphoid malignancies and 2% of all malignancies. It is twice as common...